Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab and Pertuzumab in HER2-positive Breast Cancer
NCT07187752Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of trastuzumab and pertuzumab in breast cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: Total Pathological Complete Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07187752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187752.